Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;7(2):186-195.
doi: 10.1016/S2468-1253(21)00191-6.

Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models

Affiliations

Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models

Andrea F DiMartini et al. Lancet Gastroenterol Hepatol. 2022 Feb.

Abstract

Despite its increased recognition as a major public health issue, alcohol use disorder is mostly underdiagnosed and undertreated. The undertreatment and underdiagnosis of alcohol use disorder is most concerning in the management of patients with alcohol-associated liver disease, which is one of the main medical consequences of chronic and excessive alcohol use. Dual pathology (alcohol use disorder and alcohol-associated liver disease) requires multidisciplinary care involving hepatologists and addiction specialists. Such integrated care models are widely accepted as optimal care for treating comorbid medical and mental health conditions. However, the implementation of such models in clinical practice is challenging and often represents the exception, rather than the rule, in managing patients with alcohol use disorder and alcohol-associated liver disease. Barriers at the patient, clinician, and system levels are encountered in treating patients with alcohol use disorder and alcohol-associated liver disease. In this Viewpoint, we synthesise the emerging literature on the potential barriers encountered in caring for patients with alcohol-associated liver disease and alcohol use disorder and focus on how integrated models of care could overcome these barriers. We provide our perspective on why these barriers exist and propose strategies to overcome them.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests LL reports honoraria from the UK Medical Council on Alcoholism (Editor-in-Chief for Alcohol and Alcoholism); receives book royalties from Routledge; funding from the Intramural Research Program of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism (ZIA-DA000635 and ZIA-AA000218); and employment by the National Institutes of Health. AKS reports personal fees from Gilead, Medscape Gastroenterology, CLD Foundation, Up-to-Date, and ACG; non-financial support from American Association for the Study of Liver Diseases and American Porphyria Foundation; and grants from National Institute on Alcohol Abuse and Alcoholism and National Institute of Diabetes and Digestive and Kidney Diseases.

Figures

Figure 1
Figure 1
Proposed integrated multidisciplinary care model based on expertise of the authors on management of alcohol use disorder (AUD) and of liver disease among patients with alcohol-associated liver disease (ALD). *Risk of advanced fibrosis with fibroscan is determined based on FIB-4 score ≥3.25 and / or liver stiffness measurement (LSM) of ≥15 kPa on fibroscan.(79) FIB-4: Fibrosis-4 serum score using age and values of platelets, and liver aminotransferases (AST and ALT); LSM: Liver stiffness measurement measured in kilopascals (kPa) on fibroscan; AUDIT: AUD identification test; DSM: Diagnostic and statistical manual of mental disorders. *Harmful alcohol use defined as >2 drinks/d for women and >3 drinks/d for men. One drink is defined as 12 oz. of beer, 5 oz. of wine, or 1.5 oz. of hard liquor.

Comment in

  • Digging deeper into alcohol-related deaths.
    The Lancet Gastroenterology Hepatology. The Lancet Gastroenterology Hepatology. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):107. doi: 10.1016/S2468-1253(21)00479-9. Lancet Gastroenterol Hepatol. 2022. PMID: 35026165 No abstract available.

References

    1. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–66. - PMC - PubMed
    1. Axley PD, Richardson CT, Singal AK. Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease. Clin Liver Dis. 2019;23(1):39–50. - PubMed
    1. Wong RJ, Singal AK. Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014–2019. JAMA Netw Open. 2020;3(2):e1920294. - PMC - PubMed
    1. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Netw Open. 2020;3(4):e201997. - PMC - PubMed
    1. Caputo F, Domenicali M, Bernardi M. Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease. Hepatology (Baltimore, Md). 2019;70(1):410–7. - PubMed

Publication types

MeSH terms

LinkOut - more resources